A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL

NCT06314828 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Non-Hodgkin's Lymphoma

Interventions

BIOLOGICAL: RJMty19 (CD19-CAR-DNT cells)

Sponsor

Guangdong Ruishun Biotech Co., Ltd

Collaborators

[object Object]
[object Object]
[object Object]